secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2023-07-20T23:59:59+00:00
Accession:  0001193125-23-190491
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunityBio updates Sorrento settlement terms; securities class action filed
----------------------------------------------------------------------------

- Sorrento settlement hearing set for Aug 14, 2023; two scenarios: pay judgments by Aug 31 or release claims and relinquish NANTibody interests.
- If settlement not approved, ImmunityBio will continue pursuing judgment collection; no receivables recorded as of June 30, 2023.
- Securities class action filed June 30, 2023 in S.D. Cal. alleging false statements re FDA complete response letter for Anktiva (N-803).
- Company believes class action is without merit and intends to defend vigorously; cannot estimate potential loss.
- FDA CRL cited deficiencies at third-party contract manufacturers; BLA for N-803 + BCG for bladder cancer not approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000119312523190491/0001193125-23-190491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000119312523190491/d473206d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-190491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer